Type II diabetes and metabolic syndrome in relation to head and neck squamous cell carcinoma risk: A SEER-Medicare database study

Cancer Epidemiology

Volumn 37, Issue 4, 2013, Pages 428-433

  Stott Miller, Marni ^a   Chen, Chu ^a,b,c   Schwartz, Stephen M ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; Metabolic syndrome; Oral cancer; Squamous cell carcinoma of the head and neck; Syndrome X

Indexed keywords

AGED; ARTICLE; CANCER REGISTRY; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; PRIORITY JOURNAL; SMOKING; TUMOR LOCALIZATION;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MEDICARE; METABOLIC SYNDROME X; ODDS RATIO; RISK; SEER PROGRAM; UNITED STATES;

EID: 84878927773     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2013.03.006     Document Type: Article

References (47)

1. Vigneri P., Frasca F., Sciacca L., Pandini G., Vigneri R. Diabetes and cancer. Endocr Relat Cancer 2009, 16(4):1103-1123.
2. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2005, 365(9468):1415-1428.
3. Pais R., Silaghi H., Silaghi A.C., Rusu M.L., Dumitrascu D.L. Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastroenterol 2009, 15(41):5141-5148.
4. Aleksandrova K., Boeing H., Jenab M., Bueno-de-Mesquita H.B., Jansen E., van Duijnhoven F., et al. Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study. Cancer Prev Res (PA) 2011, 4(11):1873-1883.
5. Kabat G.C., Kim M., Chlebowski R.T., Khandekar J., Ko M.G., McTiernan A., et al. A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2009, 18(7):2046-2053.
6. Xue F., Michels K.B. Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr 2007, 86(3):s823-s835.
7. Johansen D., Stocks T., Jonsson H., Lindkvist B., Björge T., Concin H., et al. Metabolic factors and the risk of pancreatic cancer: a prospective analysis of almost 580,000 men and women in the Metabolic Syndrome and Cancer Project. Cancer Epidemiol Biomarkers Prev 2010, 19(9):2307-2317.
8. Rosato V., Zucchetto A., Bosetti C., Dal Maso L., Montella M., Pelucchi C., et al. Metabolic syndrome and endometrial cancer risk. Ann Oncol 2011, 22(4):884-889.
9. Welzel T.M., Graubard B.I., Zeuzem S., El-Serag H.B., Davila J.A., McGlynn K.A. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-medicare database. Hepatology 2011, 54(2):463-471.
10. Haffner S.M., Valdez R.A., Hazuda H.P., Mitchell B.D., Morales P.A., Stern M.P. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992, 41(6):715-722.
11. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414(6865):813-820.
12. Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004, 4(8):579-591.
13. Renehan A.G., Zwahlen M., Minder C., O'Dwyer S.T., Shalet S.M., Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004, 363(9418):1346-1353.
14. de Rekeneire N., Peila R., Ding J., Colbert L.H., Visser M., Shorr R.I., et al. Diabetes, hyperglycemia, and inflammation in older individuals: the health, aging and body composition study. Diabetes Care 2006, 29(8):1902-1908.
15. O'Byrne K.J., Dalgleish A.G. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001, 85(4):473-483.
16. Cowey S., Hardy R.W. The metabolic syndrome: a high-risk state for cancer?. Am J Pathol 2006, 169(5):1505-1522.
17. Stott-Miller M., Chen C., Chuang S.C., Lee Y.C., Boccia S., Brenner H., et al. History of diabetes and risk of head and neck cancer: a pooled analysis from the international head and neck cancer epidemiology consortium. Cancer Epidemiol Biomarkers Prev 2012, 21(2):294-304.
18. Wideroff L., Gridley G., Mellemkjaer L., Chow W.H., Linet M., Keehn S., et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997, 89(18):1360-1365.
19. Suba Z. Gender-related hormonal risk factors for oral cancer. Pathol Oncol Res 2007, 13(3):195-202.
20. Warren J.L., Klabunde C.N., Schrag D., Bach P.B., Riley G.F. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002, 40. IV-3-IV-18.
21. Engels E.A., Pfeiffer R.M., Ricker W., Wheeler W., Parsons R., Warren J.L. Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the U.S. elderly. Am J Epidemiol 2011, 174(7):860-870.
22. Surveillance, Epidemiology, and End Results (SEER) Program () Research Data (1973-2008), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2011, based on the November 2010 submission. http://www.seer.cancer.gov/.
23. Percy C. International Classification of Diseases for Oncology (ICD-O-3) 1990, World Health Organization, Geneva, Switzerland. 3rd ed.
24. Harris M.I., Cowie C.C., Eastman R. Health-insurance coverage for adults with diabetes in the U.S. population. Diabetes Care 1994, 17(6):585-591.
25. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001, 285:2486-2497.
26. Royston P. Multiple imputation of missing values. Stata J 2004, 4:227-241.
27. Yen A.M., Chen S.L., Chiu S.Y., Chen H.H. Association between metabolic syndrome and oral pre-malignancy: a community- and population-based study (KCIS No. 28). Oral Oncol 2011, 47(7):625-630.
28. Dietrich T., Reichart P.A., Scheifele C. Clinical risk factors of oral leukoplakia in a representative sample of the U.S. population. Oral Oncol 2004, 40:158-163.
29. Dikshit R.P., Ramadas K., Hashibe M., Thomas G., Somanathan T., Sankaranarayanan R. Association between diabetes mellitus and pre-malignant oral diseases: A cross sectional study in Kerala, India. Int J Cancer 2006, 118:453-457.
30. Albrecht M., Bánóczy J., Dinya E., Tamás G. Occurrence of oral leukoplakia and lichen planus in diabetes mellitus. J Oral Pathol Med 1992, 21(8):364-366.
31. Silverman S.J., Gorsky M., Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 1984, 53:563-568.
32. Reibel J. Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med 2003, 14:47-62.
33. Hillier T.A., Pedula K.L. Complications in young adults with early-onset type 2 diabetes: losing the relative protection of youth. Diabetes Care 2003, 26(11):2999-3005.
34. Hashibe M., Brennan P., Benhamou S., Castellsague X., Chen C., Curado M.P., et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 2007, 99(10):777-789.
35. Sturgis E.M., Wei Q., Spitz M.R. Descriptive epidemiology and risk factors for head and neck cancer. Semin Oncol 2004, 31(6):726-733.
36. Schoenborn C.A., Vickerie J.L., Barnes P.M. Cigarette smoking behavior of adults: United States, 1997-1998. Advance data from vital and health statistics; no. 331 2003, National Center for Health Statistics, Hyattsville, MD.
37. Djoussé L., Biggs M.L., Mukamal K.J., Siscovick D.S. Alcohol consumption and type 2 diabetes among older adults: the Cardiovascular Health Study. Obesity (Silver Spring) 2007, 15(7):1758-1765.
38. Paganini-Hill A., Kawas C.H., Corrada M.M. Type of alcohol consumed, changes in intake over time and mortality: the Leisure World Cohort Study. Age Ageing 2007, 36(2):203-209.
39. Kahn S.E., Hull R.L., Utzschneider K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444(7121):840-846.
40. Stumvoll M., Goldstein B.J., van Haeften T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005, 365(9467):1333-1346.
41. Gaudet M.M., Olshan A.F., Chuang S.C., Berthiller J., Zhang Z.F., Lissowska J., et al. Body mass index and risk of head and neck cancer in a pooled analysis of case-control studies in the International Head and Neck Cancer Epidemiology (INHANCE) Consortium. Int J Epidemiol 2010, 39(4):1091-1102.
42. Wilkins T.L., Rust G.S., Sambamoorthi U. Changing BMI categories and healthcare expenditures among elderly medicare beneficiaries. Obesity (Silver Spring) 2012, 20(6):1240-1248.
43. Davila J.A., Morgan R.O., Shaib Y., McGlynn K.A., El-Serag H.B. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005, 54(4):533-539.
44. Wang C., Wang X., Gong G., Ben Q., Qiu W., Chen Y., et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer 2012, 130(7):1639-1648.
45. Decensi A., Puntoni M., Goodwin P., Cazzaniga M., Gennari A., Bonanni B., et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (PA) 2010, 3(11):1451-1461.
46. Currie C.J., Poole C.D., Gale E.A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009, 52(9):1766-1777.
47. Surveillance, Epidemiology and End Results (SEER). [accessed 01.09.12]. http://seer.cancer.gov/.